AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 120_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 33_CD Company_NN information_NN Company_NN Balance_NNP Sheet_NNP 2004_CD 2003_CD At_IN 31_CD December_NNP Notes_NNP $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS Fixed_VBN asset_NN investments_NNS 33_CD 7,745_CD 6,940_CD Current_JJ assets_NNS Debtors_NNS other_JJ 25_CD 7_CD Debtors_NNS amounts_VBZ owed_VBN by_IN subsidiaries_NNS 23,228_CD 25,339_CD 23,253_CD 25,346_CD Total_JJ assets_NNS 30,998_CD 32,286_CD Creditors_NNS due_JJ within_IN one_CD year_NN Non-trade_JJ creditors_NNS 33_CD 3,590_CD 3,120_CD Net_JJ current_JJ assets_NNS 19,663_CD 22,226_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 27,408_CD 29,166_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Loans_NNPS owed_VBD to_TO subsidiaries_NNS 33 283 295_CD Loans_NNS external_JJ 33_CD 747_CD 1,030_CD 295_CD Net_JJ assets_NNS 26,378_CD 28,871_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 34 411 423_CD Share_NN premium_NN account_NN 33 550 449_CD Capital_NNP redemption_NN reserve_NN 33_CD 36_CD 23_CD Other_JJ reserves_NNS 33_CD 1,841_CD 1,841_CD Profit_NN and_CC loss_NN account_NN 33_CD 23,540_CD 26,135_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 26,378_CD 28,871_CD The_DT Financial_NNP Statements_NNP on_IN pages_NNS 72_CD to_TO 135_CD were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 27_CD January_NNP 2005_CD and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Director_NNP Director_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 121_CD 33_CD Company_NN information_NN continued_VBD Deferred_JJ taxation_NN The_DT parent_NN company_NN had_VBD deferred_VBN tax_NN assets_NNS of_IN $_$ 25m_CD at_IN 31_CD December_NNP 2004_CD ._.
Investments_NNP in_IN subsidiaries_NNS Fixed_VBN asset_NN investments_NNS Shares_NNP Loans_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN at_IN beginning_NN of_IN year_NN 6,645_CD 295_CD 6,940_CD Additions_NNS 70 747 817_CD Disposals_NNS and_CC other_JJ movements_NNS 12_CD 12_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2004_CD 6,715_CD 1,030_CD 7,745_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 6,645_CD 295_CD 6,940_CD Non-trade_JJ creditors_NNS 2004_CD 2003_CD $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS unsecured_JJ 4_CD 3_CD Other_JJ creditors_NNS 116_CD 154_CD Amounts_NNS owed_VBN to_TO subsidiaries_NNS 2,409_CD 2,049_CD Dividends_NNS to_TO shareholders_NNS 1,061_CD 914_CD 3,590_CD 3,120_CD Loans_NNPS owed_VBD to_TO subsidiaries_NNS Repayment_NN 2004_CD 2003_CD Dates_NNPS $_$ m_CD $_$ m_CD Loans_JJ unsecured_JJ US_NNP dollars_NNS 7.2_CD %_NN loan_NN 2023 283 295_CD Loans_NNS external_JJ 5.4_CD %_NN Callable_JJ bond_NN 2014_CD 747_CD Total_JJ loans_NNS 1,030_CD 295_CD Loans_NNPS or_CC instalments_NNS thereof_RB are_VBP repayable_JJ :_: After_IN five_CD years_NNS from_IN balance_NN sheet_NN date_NN 1,030_CD 295_CD From_IN two_CD to_TO five_CD years_NNS From_IN one_CD to_TO two_CD years_NNS Total_JJ unsecured_JJ 1,030_CD 295_CD Total_JJ due_JJ within_IN one_CD year_NN Total_JJ loans_NNS 1,030_CD 295_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 122_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 33_CD Company_NN information_NN continued_VBD Share_NNP Capital_NNP Profit_NNP premium_NN redemption_NN Other_JJ and_CC loss_NN 2004_CD 2003_CD Reserves_NNS account_VBP reserve_NN reserves_NNS account_VBP Total_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN beginning_NN of_IN year_NN 449_CD 23_CD 1,841_CD 26,135_CD 28,448_CD 30,655_CD Net_JJ gains_NNS for_IN the_DT year_NN 1,172_CD 1,172_CD 244_CD Dividends_NNPS 1,555_CD 1,555_CD 1,350_CD Share_NN re-purchases_VBZ 13_CD 2,212_CD 2,199_CD 1,147_CD Share_NN premiums_NNS 101_CD 101_CD 46_CD At_IN end_NN of_IN year_NN 550_CD 36_CD 1,841_CD 23,540_CD 25,967_CD 28,448_CD Distributable_JJ reserves_NNS at_IN end_NN of_IN year_NN 591_CD 617_CD 1,208_CD 1,592_CD As_IN permitted_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ profit_NN and_CC loss_NN account_NN ._.
At_IN 31_CD December_NNP 2004_CD $_$ 22,923_CD m_NN 31_CD December_NNP 2003_CD $_$ 25,032_CD m_NN of_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN was_VBD not_RB available_JJ for_IN distribution_NN ._.
The_DT majority_NN of_IN this_DT non-distributable_JJ amount_NN relates_VBZ to_TO profit_VB arising_VBG on_IN the_DT sale_NN of_IN Astra_NNP AB_NNP to_TO a_DT subsidiary_NN in_IN 1999_CD ,_, which_WDT becomes_VBZ distributable_JJ as_IN the_DT underlying_VBG receivable_NN is_VBZ settled_VBN ._.
During_IN 2004_CD ,_, $_$ 2,109_CD m_NN of_IN the_DT profit_NN was_VBD realized_VBN by_IN repayment_NN ._.
Subsequent_JJ to_TO the_DT year_NN end_NN ,_, a_DT further_JJ $_$ 1,625_CD m_NN was_VBD repaid_VBN on_IN 25_CD January_NNP 2005_CD ,_, resulting_VBG in_IN additional_JJ distributable_JJ reserves_NNS not_RB included_VBD in_IN the_DT figures_NNS above_IN ._.
Included_VBN in_IN other_JJ reserves_NNS is_VBZ a_DT special_JJ reserve_NN of_IN $_$ 157m_CD ,_, arising_VBG on_IN the_DT redenomination_NN of_IN share_NN capital_NN in_IN 1999_CD ._.
2004_CD 2003_CD Reconciliation_NNP of_IN movement_NN in_IN shareholders_NNS funds_NNS $_$ m_CD $_$ m_CD Shareholders_NNS funds_NNS at_IN beginning_NN of_IN year_NN 28,871_CD 31,084_CD Net_JJ gains_NNS for_IN the_DT financial_JJ year_NN 1,172_CD 244_CD Dividends_NNPS 1,555_CD 1,350_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 102_CD 47_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 2,212_CD 1,154_CD Net_JJ reduction_NN in_IN shareholders_NNS funds_NNS 2,493_CD 2,213_CD Shareholders_NNS funds_NNS at_IN end_NN of_IN year_NN 26,378_CD 28,871_CD
